PM00104 (Zalypsis(®)): A Marine Derived Alkylating Agent

PM00104 (Zalypsis(®)) is a synthethic tetrahydroisoquinolone alkaloid, which is structurally similar to many marine organisms. The compound has been proposed as a potential chemotherapeutic agent in the treatment of solid human tumors and hematological malignancies. PM00104 is a DNA binding agent, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Petek, Bradley J., Jones, Robin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6270769/
https://www.ncbi.nlm.nih.gov/pubmed/25153860
http://dx.doi.org/10.3390/molecules190812328
_version_ 1783376774852247552
author Petek, Bradley J.
Jones, Robin L.
author_facet Petek, Bradley J.
Jones, Robin L.
author_sort Petek, Bradley J.
collection PubMed
description PM00104 (Zalypsis(®)) is a synthethic tetrahydroisoquinolone alkaloid, which is structurally similar to many marine organisms. The compound has been proposed as a potential chemotherapeutic agent in the treatment of solid human tumors and hematological malignancies. PM00104 is a DNA binding agent, causing inhibition of the cell cycle and transcription, which can lead to double stranded DNA breaks. After rigorous pre-clinical testing, the drug has been evaluated in a number of phase II clinical trials. This manuscript provides a review of current trials and appraises the efficacy of PM00104 as a future cancer treatment.
format Online
Article
Text
id pubmed-6270769
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62707692018-12-27 PM00104 (Zalypsis(®)): A Marine Derived Alkylating Agent Petek, Bradley J. Jones, Robin L. Molecules Review PM00104 (Zalypsis(®)) is a synthethic tetrahydroisoquinolone alkaloid, which is structurally similar to many marine organisms. The compound has been proposed as a potential chemotherapeutic agent in the treatment of solid human tumors and hematological malignancies. PM00104 is a DNA binding agent, causing inhibition of the cell cycle and transcription, which can lead to double stranded DNA breaks. After rigorous pre-clinical testing, the drug has been evaluated in a number of phase II clinical trials. This manuscript provides a review of current trials and appraises the efficacy of PM00104 as a future cancer treatment. MDPI 2014-08-15 /pmc/articles/PMC6270769/ /pubmed/25153860 http://dx.doi.org/10.3390/molecules190812328 Text en © 2014 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Petek, Bradley J.
Jones, Robin L.
PM00104 (Zalypsis(®)): A Marine Derived Alkylating Agent
title PM00104 (Zalypsis(®)): A Marine Derived Alkylating Agent
title_full PM00104 (Zalypsis(®)): A Marine Derived Alkylating Agent
title_fullStr PM00104 (Zalypsis(®)): A Marine Derived Alkylating Agent
title_full_unstemmed PM00104 (Zalypsis(®)): A Marine Derived Alkylating Agent
title_short PM00104 (Zalypsis(®)): A Marine Derived Alkylating Agent
title_sort pm00104 (zalypsis(®)): a marine derived alkylating agent
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6270769/
https://www.ncbi.nlm.nih.gov/pubmed/25153860
http://dx.doi.org/10.3390/molecules190812328
work_keys_str_mv AT petekbradleyj pm00104zalypsisamarinederivedalkylatingagent
AT jonesrobinl pm00104zalypsisamarinederivedalkylatingagent

Ejemplares similares